XOMA Royalty (XOMA) Enterprise Value (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Enterprise Value came in at -$66.1 million in Q1 2026, down 812.47% year-on-year from $9.3 million in Q1 2025, and up 3.29% quarter-over-quarter from -$68.3 million in Q4 2025.
XOMA Royalty (XOMA) Enterprise Value (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Enterprise Value across 17 years of filings, most recently posting -$66.1 million for Q1 2026.
- Enterprise Value for Q1 2026 came in at -$66.1 million, down 812.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.1 million (down 812.47% YoY), and the FY2025 annual result was -$68.3 million, down 804.0% from the prior year.
- Enterprise Value came in at -$66.1 million for Q1 2026 at XOMA Royalty, up from -$68.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $9.7 million in Q4 2024 to a low of -$153.4 million in Q4 2023.
- The 5-year median for Enterprise Value is -$35.5 million (2025), against an average of -$55.6 million.
- Across the five-year window, Enterprise Value jumped 106.33% in 2024 and tumbled 812.47% in 2026, its largest moves.
- XOMA Royalty's Enterprise Value stood at -$30.6 million in 2022, then plunged by 400.9% to -$153.4 million in 2023, then surged by 106.33% to $9.7 million in 2024, then plunged by 804.0% to -$68.3 million in 2025, then increased by 3.29% to -$66.1 million in 2026.
- The last three Enterprise Value figures came in at -$66.1 million (Q1 2026), -$68.3 million (Q4 2025), and -$35.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -584.73 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -66.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.08 Mn |
| Dec 31, 2025 | -68.33 Mn |
| Sep 30, 2025 | -35.45 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | -7.24 Mn |
| Dec 31, 2024 | 9.71 Mn |
| Sep 30, 2024 | -4.80 Mn |
| Jun 30, 2024 | -144.60 Mn |
| Mar 31, 2024 | -136.43 Mn |
| Dec 31, 2023 | -153.45 Mn |
| Sep 30, 2023 | -33.69 Mn |
| Jun 30, 2023 | -31.72 Mn |
| Mar 31, 2023 | -44.61 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -30.64 Mn |
| Jun 30, 2022 | -83.71 Mn |
| Mar 31, 2022 | -88.60 Mn |
| Dec 31, 2021 | -94.10 Mn |
| Sep 30, 2021 | -72.17 Mn |
| Jun 30, 2021 | -81.26 Mn |